Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 987
countries
28
conditions
2 109

121 trials match your criteria

Non-small cell lung cancer

Recruiting

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm malignant

Recruiting

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Non-small cell lung cancer metastatic

Recruiting

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Malignant mast cell neoplasm

Recruiting

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Recruiting

Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Recruiting

Study of STK-012 Alone and Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm malignant+2

Recruiting

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.